Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Lung Neoplasms 2 Refractory/Relapse Neuroblastoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteoporosis 1 Neuroendocrine Tumors 1 Neoplasms, Squamous Cell 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma 1 Lymphoma 1 Infertility 1 Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1 Breast Neoplasms 1

Interventions

lutetium Lu 177 dotatate 29 Everolimus 19 Temozolomide 11 gallium Ga 68 dotatate 10 Nivolumab 10 Magnetic Resonance Spectroscopy 10 Capecitabine 9 pembrolizumab 8 lanreotide 8 Positron Emission Tomography Computed Tomography 8 cabozantinib 7 3-Iodobenzylguanidine 7 177Lu-octreotide, DOTA(0)-Tyr(3)- 7 Somatostatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 telotristat ethyl 5 lenvatinib 5 Octreotide 5 Lutetium-177 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 Carboplatin 5 avelumab 4 Positron-Emission Tomography 4 Ipilimumab 4 Bevacizumab 4 surufatinib 3 pasireotide 3 fluorodopa F 18 3 copper dotatate CU-64 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neuroendocrine Tumors × Biological Products × Clear all

NCT07366658 2026-01-26

NEUK203-13

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1 Not yet recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡